Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Association between Type D personality and outcomes in patients with non-ischemic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Strategies to improve patient-reported outcome completion rates in longitudinal studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The effect of nature exposure on the mental health of patients: a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Measuring HRQoL following heart valve surgery: the HeartQoL questionnaire is a valid and reliable core heart disease instrument

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hydroxylated Long-Chain Acylcarnitines are Biomarkers of Mitochondrial Myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. POPDC3 Gene Variants Associate with a New Form of Limb Girdle Muscular Dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Henning Andersen
  • Renato Mantegazza
  • Jing Jing Wang
  • Fanny O'Brien
  • Kaushik Patra
  • James F Howard
  • REGAIN Study Group
  • John Vissing (Medlem af forfattergruppering)
  • Nanna Witting (Medlem af forfattergruppering)
Vis graf over relationer

PURPOSE: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints.

METHODS: Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n = 62; placebo, n = 63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26.

RESULTS: At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients.

CONCLUSIONS: Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624.

OriginalsprogEngelsk
TidsskriftQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Vol/bind28
Udgave nummer8
Sider (fra-til)2247-2254
Antal sider8
ISSN0962-9343
DOI
StatusUdgivet - aug. 2019

ID: 58457638